Copyright
©The Author(s) 2021.
World J Clin Oncol. May 24, 2021; 12(5): 342-354
Published online May 24, 2021. doi: 10.5306/wjco.v12.i5.342
Published online May 24, 2021. doi: 10.5306/wjco.v12.i5.342
Figure 4 Effect of royal jelly, thymoquinone and combinations on caspase 3 cleavage in MDA-MB-231 human breast cancer cells.
A: Immunofluorescence micrographs of cleaved caspase 3 expression at 24 h after treatment. Red indicates cleaved caspase 3 expression and blue indicates nuclei counter stained by 4′,6-diamidino-2-phenylindole. Arrows indicate apoptotic nuclei. Nuclei were visualized by confocal Zeiss Axio microscope, 40 × oil immersion with scale bar = 50 µmol/L; B: Quantification of cleaved caspase 3 in MDA-MB-231 cells at 24 h of treatment with different concentrations of royal jelly, thymoquinone, and their combinations. Data shown are an average of 3 independent experiments expressed as mean ± standard error of the mean. Asterisks represent statistically significant results, (aP < 0.05, bP < 0.01, cP < 0.001). RJ: Royal jelly; TQ: Thymoquinone.
- Citation: Moubarak MM, Chanouha N, Abou Ibrahim N, Khalife H, Gali-Muhtasib H. Thymoquinone anticancer activity is enhanced when combined with royal jelly in human breast cancer. World J Clin Oncol 2021; 12(5): 342-354
- URL: https://www.wjgnet.com/2218-4333/full/v12/i5/342.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i5.342